HER2/EGFR in Cancer Research

Effects of N361 Glycosylation on Epidermal Growth Factor Receptor Biological Function

This study investigates how N361 glycosylation affects EGFR function, finding that the N361A mutation reduces proliferation and ligand sensitivity while increasing co-localization with HER2 and resistance to antibody inhibition.

Metabolic Alterations driven by PFKFB3 upregulation confer Resistance to Trastuzumab in HER2-Positive Breast Cancer.

This study identifies PFKFB3 upregulation as a driver of trastuzumab resistance in HER2+ breast cancer through metabolic rewiring and reduced ADCC, with clinical correlations to poor survival.

Recurrent cancer-associated ERBB4 mutations are transforming and confer resistance to targeted therapies

This study identifies recurrent ERBB4 mutations with oncogenic potential and resistance to targeted therapies, suggesting clinical implications for treatment strategies.

ErbB2/HER2 governs CDK4 inhibitor sensitivity and timing and irreversibility of G1/S transition by altering c-Myc and cyclin D function

This study shows how ErbB2 levels affect CDK4 inhibitor sensitivity and the timing of G1/S transition by altering c-Myc and cyclin D function in breast cancer cells.

Integrative proteo-genomic profiling uncovers key biomarkers of lapatinib resistance in HER2-positive breast cancer

The paper identifies a nine-marker signature of lapatinib resistance in HER2-positive breast cancer using integrative multi-omics analysis, revealing novel biomarkers and chromatin dynamics associated with drug resistance.

Quantification of HER2-low and ultra-low expression in breast cancer specimens by quantitative IHC and artificial intelligence

This paper develops qIHC and AI-based methods to quantify HER2 expression in breast cancer, showing significant differences between IHC categories and high spatial heterogeneity.

ECD co-operates with ERBB2 to promote tumorigenesis through upregulation of unfolded protein response and glycolysis

This study shows ECD and ERBB2 cooperate in breast cancer by enhancing unfolded protein response and glycolysis through direct mRNA binding and increased glucose uptake.

Erbin interacts with NHERF1 and Ezrin to stabilize a membrane ErbB2 signaling complex in HER2-positive breast cancer

The paper shows Erbin interacts with NHERF1 and Ezrin to stabilize a membrane HER2 signaling complex in HER2-positive breast cancer, enhancing HER2 stability and transforming ability.

NOK promotes tumorigenesis through coordinating epidermal growth factor receptor to boost the downstream signaling in breast cancer

This study shows NOK promotes breast cancer by enhancing EGFR signaling through direct interaction and phosphorylation of downstream proteins like STAT3, STAT5, and Erk1/2.

Low-affinity ligands of the epidermal growth factor receptor are long-range signal transmitters during collective cell migration of epithelial cells

This study shows low-affinity EGFRLs like EREG and AREG transmit signals more efficiently than high-affinity ligands during collective cell migration and wound healing.

Rational design of HER2-targeted combination therapies to reverse drug resistance in fibroblast-protected HER2+ breast cancer cells.

This study identifies PAI1 and PLK1 as predictors of fibroblast-mediated resistance in HER2+ breast cancer and shows that targeting these proteins with lapatinib improves treatment efficacy.

HER4 is a high affinity dimerization partner for all EGFR/HER/ErbB-family proteins

This study uses PIE-FCCS to show HER4 directly interacts with all HER family members in live cells, even without ligands, suggesting HER4 is a preferred dimerization partner.

Nucleocytoplasmic transport of active HER2 causes fractional escape from the DCIS-like state

The paper identifies how HER2 nucleocytoplasmic transport dynamics drive escape from DCIS-like state through systems-level feedback mechanisms.

Activity of EGFR transmembrane region variants indicates specific transmembrane dimers are not required for EGFR activity

The paper investigates the role of specific transmembrane dimers in EGFR activity and finds that many transmembrane sequences are compatible with EGFR function without requiring specific dimer conformations.

Origin of diverse phosphorylation patterns in the ERBB system

The paper investigates how differences in ERBB receptor expression and phosphorylation rates contribute to diverse phosphorylation dynamics across organs.

Validation of HER2 status in whole genome sequencing data of breast cancers with AI-driven, ploidy-corrected approach

The paper develops an AI-driven, ploidy-corrected method using whole genome sequencing to accurately determine HER2 status in breast cancer patients.

Germline ERBB3 mutation in familial non-small cell lung carcinoma: expanding the role of the ErbB family in oncogenesis.

The paper identifies a germline ERBB3 mutation in a family with hereditary non-small cell lung cancer, showing it drives oncogenesis through altered signaling.

Binding of single-mutant epidermal growth factor (EGF) ligands alter the stability of the EGF receptor dimer and promote growth signaling

This study shows that single-mutant EGF ligands alter EGFR dimer stability and signaling, supporting biased signaling theory.

Conserved Roles for Receptor Tyrosine Kinase Extracellular Regions in Regulating Receptor and Pathway Activity

The paper shows that the extracellular regions of RTKs regulate downstream signaling, with EGFR extracellular regions activating multiple RTK classes, while Fc-RTK chimeras fail to activate effectors.

Dynamical rearrangement of human epidermal growth factor receptor 2 upon antibody binding: effects on the dimerization

This study uses computational modeling to investigate how anti-HER2 antibodies affect HER2 dimerization by analyzing conformational changes in key regions of the receptor.

Modelling the role of dual specificity phosphatases in Herceptin resistant breast cancer cell lines

The paper models how DUSP overexpression contributes to Herceptin resistance in breast cancer and identifies potential therapeutic strategies.

A conformational sensor based on genetic code expansion reveals an autocatalytic component in EGFR activation

The paper develops a FRET-based sensor to study EGFR conformational changes and identifies an autocatalytic mechanism in EGFR activation.